Who Paid My Doc
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
ClinicalTrials.gov NCT04492020
Research payments
$481,755
Through program year 2024, $481,755 in research payments was reported against Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants, across 199 payments, paid by AbbVie, Inc..
- Paid by
- AbbVie, Inc.
- ClinicalTrials.gov
- NCT04492020
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $8,481 | 1 |
| 2023 | Research | $64,710 | 15 |
| 2022 | Research | $408,564 | 183 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David Damian Bryan, TX Named on 9 payments
- Kerry Knievel Phoenix, AZ Named on 8 payments
- Arifulla Khan Bellevue, WA Named on 7 payments
- Joe Pouzar Houston, TX Named on 7 payments
- Michael Downing Dallas, TX Named on 7 payments
- Sherry Soefje Oceanside, CA Named on 5 payments
- Hayes Williams Vestavia, AL Named on 5 payments
- Ashok Patel Toms River, NJ Named on 4 payments
- Jon Finley Stockbridge, GA Named on 4 payments
- Gigi Lefebvre St Petersburg, FL Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.